Theriva Biologics, Inc.

Contributing Author

Recent Articles by Theriva Biologics, Inc.

Oct-24	Theriva Biologics Provides Response to Unusual Market Action TOVX GlobeNewswire
Oct-16	Theriva Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds TOVX GlobeNewswire
Oct-13	Theriva Biologics Announces Upcoming Presentations at Medical Meetings TOVX GlobeNewswire
Oct-06	Theriva Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) TOVX GlobeNewswire
Aug-11	Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
May-27	Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer TOVX GlobeNewswire
May-14	Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
May-08	Theriva Biologics Announces Closing of $7.5 Million Public Offering TOVX GlobeNewswire
May-07	Theriva Biologics Announces Pricing of $7.5 Million Public Offering TOVX GlobeNewswire
May-07	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients TOVX GlobeNewswire